Biocon, Advaxis To Develop Cancer Immunotherapy Against HPV

Biocon and Advaxis will co-develop and commercialize ADXS-HPV, a novel cancer immunotherapy for the treatment of HPV.

AsianScientist (Jan. 24, 2014) – Indian biotechnology company Biocon Ltd. and Advaxis, Inc. have entered into an agreement for the co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV).

“Biocon is committed to finding solutions for women’s health issues. This partnership will enable us to develop ADXS–HPV a novel immunotherapy to combat cervical cancer in women. It is a promising technology that has the ability to suppress the tumor inside the micro-environment, and can be leveraged for developing several other novel therapeutics to address various unmet medical needs of patients in India and other emerging markets,” said Kiran Mazumdar-Shaw, chairperson and managing director of Biocon.

Biocon will also apply Advaxis’ immunotherapy technology to develop novel therapeutics for various unmet medical needs.

“We are excited to partner with Biocon, one of the world’s leading biotechnology companies and the largest biotechnology company in India to bring our innovative cancer immunotherapy for cervical cancer to women with few alternatives,” said Daniel J. O’Connor, CEO of Advaxis. “This agreement gives us reach into key markets where the number of patients with HPV-associated cancers is overwhelming.”

——

Source: Biocon.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist